As per attachment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 2.1 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Norris Medicines Ltd approved audited financial results for the quarter and year ended March 31, 2025. Total income for FY25 stood at Rs. 588.15 lakhs vs Rs. 566.40 lakhs in FY24, a modest ~3.8% growth. However, the company reported a net loss of Rs. 123.75 lakhs for FY25, slightly wider than Rs. 118.68 lakhs loss in FY24. The auditor M/s. Bahedia & Associates issued an unmodified (clean) opinion with no qualifications. An Emphasis of Matter paragraph was included in the auditor's report, though the specific content was not detailed in the filing. Operating cash flow was positive at Rs. 29.85 lakhs. Related party transactions for the half-year ended March 31, 2025 were disclosed separately in the Integrated Filing.
Shareholders should note that the company continues to report losses and its net worth is significantly negative (other equity of Rs. -2,479 lakhs against share capital of Rs. 992 lakhs), meaning accumulated losses far exceed capital. While the audit opinion is clean, the persistent losses and eroded equity base raise concerns about long-term financial sustainability.